Daniel A. Ermann
( out of 489 reviews )

Daniel A. Ermann, MD

Languages spoken: English

Clinical Locations

Primary Location

Huntsman Cancer Institute - Cancer Research North

2D, Hematology
2000 Circle of Hope
Salt Lake City , UT 84112
801-585-2626
Get Directions

Daniel Ermann, MD joined the Division of Hematology/Hematologic Malignancies as an Associate Professor in 2023 after completing his Hematology/Oncology fellowship at the Huntsman Cancer Institute of the University of Utah. Dr. Ermann’s clinical expertise is focused on patients with chronic lymphocytic leukemia (CLL) and other forms of non-Hodgkin lymphoma (NHL). He is passionate about working towards a cure for these malignancies. Dr. Ermann is currently the physician lead of the CLL clinical trials program at Huntsman Cancer Institute. His primary research interests include; implementing new targeted therapies for patients with CLL and lymphoma, evaluating novel treatment combinations, and developing supportive clinical trials for the complications of CLL. Dr. Ermann's research focus is to develop and implement ground-breaking clinical trials that can lead to new standards-of-care/treatments for CLL and NHL patients. Dr. Ermann is the principal investigator on more than 8 ongoing clinical trials at Huntsman Cancer Institute and is involved in the national SWOG CLL Working Group which develops and opens important trials for CLL patients around the world. He is also focused on evaluating and improving the outcomes and research, on current standards-of-care across the spectrum of lymphoma management. Dr. Ermann is originally from Pennsylvania where he graduated from the University of Pittsburgh. He earned his medical degree from St. George’s University prior to completing his Internal Medicine residency training at Creighton University in Omaha, Nebraska.

To schedule an appointment: New Patients: 801-585-6906. Returning Patients: 801-585-2626 or schedule through MyChart.

For questions regarding our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist (801) 587-4630.

Specialties

Board Certification

American Board of Internal Medicine (Internal Medicine)
American Board of Internal Medicine (Sub: Hematology)
American Board of Internal Medicine (Sub: Medical Oncology)
National Board of Medical Examiners

Patient Rating

Patients consistently describe Dr. Ermann as highly knowledgeable about CLL and current treatments and thorough in evaluating complex cases. Reviewers emphasize clear, patient explanations, attentive listening, and a reassuring, compassionate manner that leaves them feeling informed and comfortable. Several comments also note his responsiveness and personalized approach, including taking time to answer questions and follow up directly.

Generated via Patient Reviews

5.0 /5
( out of 489 reviews )

The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers. The scale on which responses are measured is 1 to 5 with 5 being the best score.

Daniel Ermann, MD joined the Division of Hematology/Hematologic Malignancies as an Associate Professor in 2023 after completing his Hematology/Oncology fellowship at the Huntsman Cancer Institute of the University of Utah. Dr. Ermann’s clinical expertise is focused on patients with chronic lymphocytic leukemia (CLL) and other forms of non-Hodgkin lymphoma (NHL). He is passionate about working towards a cure for these malignancies. Dr. Ermann is currently the physician lead of the CLL clinical trials program at Huntsman Cancer Institute. His primary research interests include; implementing new targeted therapies for patients with CLL and lymphoma, evaluating novel treatment combinations, and developing supportive clinical trials for the complications of CLL. Dr. Ermann's research focus is to develop and implement ground-breaking clinical trials that can lead to new standards-of-care/treatments for CLL and NHL patients. Dr. Ermann is the principal investigator on more than 8 ongoing clinical trials at Huntsman Cancer Institute and is involved in the national SWOG CLL Working Group which develops and opens important trials for CLL patients around the world. He is also focused on evaluating and improving the outcomes and research, on current standards-of-care across the spectrum of lymphoma management. Dr. Ermann is originally from Pennsylvania where he graduated from the University of Pittsburgh. He earned his medical degree from St. George’s University prior to completing his Internal Medicine residency training at Creighton University in Omaha, Nebraska.

To schedule an appointment: New Patients: 801-585-6906. Returning Patients: 801-585-2626 or schedule through MyChart.

For questions regarding our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist (801) 587-4630.

Board Certification and Academic Information

Academic Departments Internal Medicine -Assistant Professor (Clinical)
Academic Divisions Hematology & Hematologic Malignancies
Board Certification
American Board of Internal Medicine (Internal Medicine)
American Board of Internal Medicine (Sub: Hematology)
American Board of Internal Medicine (Sub: Medical Oncology)
National Board of Medical Examiners

Education history

Fellowship Hematology/Oncology - Huntsman Cancer institute, University of Utah School of Medicine Administrative Chief Fellow
Fellowship Hematology/Oncology - Huntsman Cancer institute, University of Utah School of Medicine Fellow
Residency Internal Medicine - Creighton University School of Medicine Chief Resident
Residency Internal Medicine - Creighton University School of Medicine Resident
Professional Medical Medicine - St. George's University School of Medicine M.D.
Undergraduate Major: Biology; Minor: Chemistry - University of Pittsburgh B.S.

Selected Publications

Journal Article

  1. Wierda WG, Dorritie KA, Gauthier J, Nath R, Kipps TJ, Riedell PA, Eradat HA, Kenderian SS, Kharfan-Dabaja MA, Shah NN, Solomon SR, Stephens DM, Ermann DA, Arnason JE, Deol A, Feldman TA, Andreadis CB, Ghosh M, Ma S, Schuster SJ, Gergis U, Vose JM, Soumerai JD, van Besien K, Tuazon SA, Perna SK, Ou SS, Ananthakrishnan R, Rane N, Papp E, Ansari S, Thompson EG, Okal A, Peiser L, Chen Y, Sengupta S, Ray PR, Wang J, Siddiqi T (2026). Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004. Blood.
  2. Hou JZ, Choksi R, Maglinte GA, Wang X, Rui PA, Suryavanshi M, Allendorf D, Patel T, Dadla A, Fontaine A, Jonglertham P, Aton L, Hagan M, Morere L, Scott J, Williams R, Ermann DA (2026). Real-world comparative effectiveness of first-line BTK inhibitors in chronic lymphocytic leukemia. Future Oncol, 1-8.
  3. Ermann DA, Stephens DM, Wang X, Varghese I, De Souza H, Sheetz C, Fu Q, Maglinte GA, Williams R, Seymour EK, van Beuge D, Shadman M, Jacobs R (2026). Real-World Outcomes Among Medicare Beneficiaries Treated with Bruton Tyrosine Kinase Inhibitors for Treatment-Naïve CLL. Oncol Ther.
  4. Swomley A, Epperla N, Horns J, Das R, Hu B, Ermann D (2026). CLO26-125: Treatment Intensity of Dose-Adjusted EPOCH-R and Its Relationship to Outcomes in Aggressive B-Cell Non-Hodgkin Lymphoma. J Natl Compr Canc Netw, 24(3.5).
  5. Ermann D, Vardell V, Zacholski E, Fegley A, Modi D, Fedak K, Sundaram S, Rajeeve S, Goyal G, Hatic H, Torka P, Ba Aqeel S, Borogovac A, MacDougall K, Kothari S, Kress A, Travers E, Chilakamarri N, Brem E, Ayyappan S, Sigmund A, Bond D, Fitzgerald L, Wagner C, Hu B, Stephens DM, Shah H (2026). Comparison of Outcomes With Novel Versus Traditional Chemotherapy Regimens for Relapsed and Refractory Classical Hodgkin Lymphoma. Clin Lymphoma Myeloma Leuk.
  6. Dranitsaris G, Peevyhouse A, Neuhalfen H, Dietz LA, Huynh C, Wahlstrom SK, Thompson SL, Teschemaker A, Shetty V, Narkhede M, Ermann D, Blau S (2025). A real-world study evaluating drug tolerability and health care resource use with acalabrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. J Med Econ, 29(1), 30-40.
  7. Stephens DM, Stewart C, Avruch L, Coombs CC, Danilov A, Hill B, Shadman M, Gerrie A, Jensen CE, Hoffmann M, Winter A, Ermann DA, Barr PM, OBrien S, Koffman B, Byrd JC (2025). Feasibility of Bruton's Tyrosine Kinase Inhibitor Discontinuation in Chronic Lymphocytic Leukemia: The Patient Perspective. Clin Lymphoma Myeloma Leuk, 25(9), e663-e667.
  8. Baron K, Anto E, Esther J, Vardell VA, Pappas L, Bock A, Ermann DA, Fitzgerald LA, Hu B, Shah HR (2025). Comparison of Real-World Outcomes in Patients with Follicular Lymphoma treated with BR vs RCHOP-like regimens. Clin Lymphoma Myeloma Leuk.
  9. Baron K, Anto E, Esther J, Vardell VA, Pappas L, Bock A, Ermann DA, Fitzgerald LA, Hu B, Shah HR (2025). Comparison of Real-World Outcomes in Patients With Follicular Lymphoma Treated With BR Versus RCHOP-Like Regimens. Clin Lymphoma Myeloma Leuk.
  10. Pierce AL, Okcu I, Nowakowski G, Tolu S, Amengual J, Ross C, Graber J, Bock A, Hu B, Ermann D (2025). HSR25-185: A Multicenter Retrospective Study of Treatment and Survival Outcomes of Patients With Secondary CNS Relapsed DLBCL in the Modern Era. J Natl Compr Canc Netw, 23(3.5).
  11. Soumerai JD, Barrientos JC, Ahn IE, Coombs CC, Gladstone DE, Hoffmann MS, Kittai AS, Jacobs RW, Lipsky A, Patel K, Rhodes JM, Skarbnik AP, Thompson MC, Ermann DA, Reville PK, Shah HR, Brown JR, Stephens DM (2024). Consensus Recommendations from the 2024 Lymphoma Research Foundation Workshop on Treatment Selection and Sequencing in CLL or SLL. Blood Adv, 9(5), 1213-1229.
  12. Samples L, Voutsinas JM MPH, Fakhri B, Khajavian S, Spurgeon SE, Stephens DM, Skarbnik AP, Mato AR, Broome C, Gopal AK, Smith SD, Lynch RC, Rainey MA, Kim MS, Barrett-Campbell O, Hemond E, Tsang M, Ermann DA, Malakhov N, Rao D, Shakib-Azar M, Morrigan B, Chauhan A, Plate T, Gooley TA, Ryan K, Lansigan F, Hill BT, Pongas G, Parikh SA, Roeker LE, Allan JN, Cheng R, Ujjani C, Shadman M (2024). Hypertension Treatment in Patients Receiving Ibrutinib: A Multicenter Retrospective Study. Blood Adv.
  13. Wagner CB, Boucher K, Nedved A, Micallef IN, Desai S, Hatic H, Goyal G, Zacholski E, Fegley A, Sigmund AM, Bond DA, Samuels C, Kamdar MK, Ba Aqeel S, Torka P, MacDougall K, Borogovac A, Rajeeve S, Sundaram S, Fedak K, Modi D, Travers E, Ayyappan S, Chilakamarri N, Brem EA, Ermann DA, Fitzgerald LA, Hu B, Stephens DM, Shah H (2023). Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes. Haematologica, 108(11), 3025-3032.
  14. Ermann DA, Vardell VA, Shah H, Fitzgerald L, Tao R, Gaffney DK, Stephens DM, Hu B (2023). Survival Outcomes of Limited-Stage Diffuse Large B-Cell Lymphoma Treated With Radiation Therapy. Clin Lymphoma Myeloma Leuk, 24(2), 94-104.e6.
  15. Vardell VA, Ermann DA, Tantravahi SK, Haaland B, McClune B, Godara A, Mohyuddin GR, Sborov DW (2022). Impact of academic medical center access on outcomes in multiple myeloma. Am J Hematol, 98(1), 41-48.
  16. Major A, Cliff ERS, Ermann DA, Durani U, Russler-Germain DA (2022). Frontline polatuzumab vedotin for diffuse large B-cell lymphoma: A survey of clinician impressions. EJHaem, 3(3), 930-935.
  17. Shadman M, Voutsinas J, Fakhri B, Khajavian S, Spurgeon S, Stephens D, Skarnbik A, Mato A, Broome C, Gopal A, Smith S, Lynch R, Rainey M, Kim S, Barrett-Campbell O, Hemond E, Tsang M, Ermann D, Malakhov N, Rao D, Shakib Azar M, Morrigan B, Chauhan A, Plate T, Gooley T, Ryan K, Lansigan F, Hill B, Pongas G, Parikh S, Roeker L, Allan J, Cheng R, Ujjani, C (2022). Treatment of Hypertension In Patients Receiving BTK Inhibitors: A Multicenter Retrospective Study. Hemasphere, 6(), 573-574.
  18. Ermann DA, Vardell VA, Kallam A, Silberstein PT, Armitage JO (2019). Academic Centers Compared With Nonacademic Centers for Patients With International Prognostic Index Risk-stratified Diffuse Large B-cell Lymphoma: A Survival Outcomes Analysis. Clin Lymphoma Myeloma Leuk, 20(4), e174-e183.
  19. Pierce TP, Ermann D, Scillia AJ, Festa A, Emami A, McInerney VK (2019). National Trends in Orthopaedic Surgery Resident Adult Case Logs. J Surg Educ, 76(3), 893-897.
  20. Vardell Noble V, Ermann DA, Griffin EK, Silberstein PT (2019). Primary Thyroid Lymphoma: An Analysis of the National Cancer Database. Cureus, 11(2), e4088.
  21. Ermann DA, Noble VV, Fazeel HM, Thomas B, Silberstein PT (2019). Presentation of a Rare Malignancy: Leiomyosarcoma of the Prostate. Fed Pract, 36(Suppl 1), S30-S33.

Book Chapter

  1. Baskaran J, Ermann DA, Silberstein PT (2019). Myeloproliferative Neoplasms. In Domino FJ (Ed.), The 5-Minute Consult (2020 / 28th Edition). Lippincott Williams & Wilkins.
  2. Pinjala A, Ermann DA, Valenta C (2019). Pancoast Tumor. In Domino FJ (Ed.), The 5-Minute Consult (2020 / 28th Edition). Lippincott Williams & Wilkins.
  3. Ermann DA, Krishnan M, Valenta C (2018). Pancoast Tumor. In Domino FJ (Ed.), The 5-Minute Consult (2019 / 27th Edition). Philadelphia: Wolters Kluwer.

Commentary

  1. Ermann DA, and Kittai AS (2024). Richter Transformation of Chronic Lymphocytic Leukemia Is a Challenging Clinical Scenario Requiring a Personalized Approach. ASCO Daily News. ASCO Daily News.

Letter

  1. Vardell VA, Ermann DA, Fitzgerald L, Shah H, Hu B, Stephens DM (2024). T-cell prolymphocytic leukemia: Epidemiology and survival trends in the era of novel treatments. [Letter to the editor]. Am J Hematol, 99(3), 494-496.
  2. Vardell VA, Ermann DA, Fitzgerald LA, Shah HR, Hu B, Stephens DM (2023). Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic leukemia. [Letter to the editor]. Am J Hematol, 98(7), E172-E174.

Abstract

  1. Ermann DA, Dranitsaris G, Blau S, Peevyhouse A, Neuhalfen H, Wahlstrom SK, Thompson SL, Teschemaker A, Shetty V, Narkhede M (2025). A real-world comparative analysis of cardiovascular (CV) safety and time to next treatment (TTNT) with acalabrutinib versus ibrutinib in treatment-naive patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). 2025 ASCO Annual Meeting. Chicago, IL [Abstract]. 43(16 (Supplement)).
  2. Steven M Bair, Mayur Narkhede, Zachary AK Frosch, Elise A Chong, Daniel A Ermann, Iris Isufi, Farrukh T Awan, Julio C Chavez, Grace N Bosma, and Diana Abbott (2023). Treatment Intensity and Outcomes in Elderly Patients with DLBCL Receiving First Line Therapy [Abstract].
  3. Sanjal H Desai, Nuttavut Sumransub, Rich Evans, Marcus P Watkins, Reem Karmali, MD, Gaurav Goyal, Mitchell E Hughes, Arushi Khurana, Francisco J Hernandez-Ilizaliturri, Joanna Zurko, Ayesha Hassan, Haris Hatic, Imran A Nizamuddin, Andrew M Evens, Andrea Carolina Anampa-Guzmn, Yi Lin, MD, Iris Isufi, Mehdi Hamadani, Saurabh A Rajguru, Naveena Lall, Aung M Tun, Brian T Hill, Deborah M Stephens, Paolo F Caimi, Daniel A Ermann, Brad S Kahl, Daniel J Landsburg, and Grzegorz S Nowakowski (2023). Improved Survival of R/R Double Hit/Triple Hit Lymphoma in the Era of CD19 Chimeric Antigen T Cell (CART) Therapy [Abstract].

News & Podcasts

Huntsman Cancer Institute News